Status:
TERMINATED
Risperidone vs. Paroxetine for Panic Attacks
Lead Sponsor:
Beth Israel Medical Center
Conditions:
Major Depressive Disorder With Panic Attacks
Panic Disorder
Eligibility:
All Genders
21-55 years
Phase:
PHASE2
Brief Summary
We are comparing the efficacy of Risperidone versus Paroxetine in the treatment of panic symptoms. The study hypothesis is that Risperidone will be a superior medicine for treating panic.
Detailed Description
Rationale Risperidone is an atypical antipsychotic drug that acts as an antagonist at 5-HT2A/2C and D2 receptors (Chouignard et al, 1993; Marder \& Meibach, 1994). In its serotonergic activity, rispe...
Eligibility Criteria
Inclusion
- Males and females, ages 21-55.
- Ability to sign an informed consent
- Diagnosis of Panic Disorder, or MDD with Panic attacks, single episode, recurrent, or chronic
- HAM-A score \>17
Exclusion
- Alcohol or substance abuse within the last 6 months
- Current diagnosis of Obsessive-Compulsive Disorder
- Current diagnosis of Schizophrenia, Schizoaffective Disorder, or Bipolar Mood Disorder
- Use of antipsychotic medications over the two months preceding enrollment in the study
- Changes in antidepressant or mood stabilizer dosing over the two months preceding enrollment in the study
- Previous adverse reaction to risperidone or paroxetine.
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2005
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00206765
Start Date
January 1 2003
End Date
July 1 2005
Last Update
October 22 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beth Israel Medical Center
New York, New York, United States, 10003